Overview

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma

Status:
Completed

Trial end date:
2008-02-01

Target enrollment:

Participant gender:

Summary

To compare the efficacy and safety of the fixed combination asthma drug Flutiform HFA MDI with its two components administered alone, fluticasone propionate and formoterol fumarate, in adult and adolescent patients with mild to moderate asthma.

Phase:

Phase 3

Details

Lead Sponsor:

SkyePharma AG

Treatments:

Fluticasone
Formoterol Fumarate
Xhance